Abstract
Hypoxemia is a significant driver of mortality and poor clinical outcomes in conditions such as brain injury and cardiac arrest in critically ill patients, including COVID-19 patients. Given the host of negative clinical outcomes attributed to hypoxemia, identifying patients likely to experience hypoxemia would offer valuable opportunities for early and thus more effective intervention. We present SWIFT (SpO2 Waveform ICU Forecasting Technique), a deep learning model that predicts blood oxygen saturation (SpO2) waveforms 5 and 30 minutes in the future using only prior SpO2 values as inputs. When tested on novel data, SWIFT predicts more than 80% and 60% of hypoxemic events in critically ill and COVID-19 patients, respectively. SWIFT also predicts SpO2 waveforms with average MSE below .0007. SWIFT provides information on both occurrence and magnitude of potential hypoxemic events 30 minutes in advance, allowing it to be used to inform clinical interventions, patient triaging, and optimal resource allocation. SWIFT may be used in clinical decision support systems to inform the management of critically ill patients during the COVID-19 pandemic and beyond.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NSF RAPID2031195. AVA acknowledges support from the NIH Medical Scientist Training Program 1T32GM136577 and the Joseph and Helen Pardoll Scholarship for MSTP Students.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by The Johns Hopkins School of Medicine IRB 00251922: RAPID Ventilator Modeling for Management of Covid 19 (SARS CoV-2) induced ARDS.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Some of the data utilized for this publication were part of the JH-CROWN: The COVID PMAP Registry which is based on the contribution of many patients and clinicians. The JH-CROWN Database is described here: https://ictr.johnshopkins.edu/coronavirus/jh-crown/ The JH-CROWN data is not publicly available due to IRB restrictions. This study was approved by The Johns Hopkins School of Medicine IRB 00251922: RAPID Ventilator Modeling for Management of Covid 19 (SARS CoV-2) induced ARDS. The other data set used is the eICU Collaborative Research Database. It is available here with access requirements: https://eicu-crd.mit.edu/gettingstarted/access/
